SHL Medical | 2019.01

SHL Group Focuses on High Volume Delivery at Drug Delivery Partnerships

SHL is set to present its market-leading auto injector offerings and expertise in final assembly and packaging services at the Drug Delivery Partnerships (DDP) 2019 conference. The three-day event will run from January 28-30 in Palm Beach Gardens, Florida, USA.

Heading into its 23rd year, the DDP conference is regarded as a prominent event where pharma companies gather to source new opportunities and most importantly, to stay at the forefront of the industry.

SHL will exhibit its broad range of advanced drug delivery devices at the conference, including the Needle Isolation Technology (NIT®) that shields users from needle-stick injuries with its pre-installed needle; the Rotaject® technology designed to deliver high volumes of drug formulations with constant force through a patented clock spring and a high-volume variation of the Molly® line – Molly®2.25.

The Molly®2.25 is a successor of the ultra-compact Molly® auto injector, owning the same preconfigured technology that offers a faster product development timeline with a larger capacity to accommodate fill volumes up to 2.25mL. The newest edition of the Molly® family is a solution for biotech and pharma companies seeking to commercialize high volume drug delivery devices in a timely manner.

"Participating in this conference allows us to connect with new and existing partners and to listen to their needs in drug delivery. SHL's contract manufacturing facility is located just some miles south of the event location so this is a hometown event for us. We invite current and future customers to visit our site when in town." said Jamie Gould, SHL's Business Development Manager.

Company experts will be at the booth to talk about SHL's unique final packaging services. As market demands increase, SHL has expanded its in-house capabilities in final assembly, labeling and packaging that ensures a streamlined process for combination products from the development stage to the final stage of becoming market-ready.

"Vertical integration is the backbone of SHL's business model, which ranges from device design, tooling fabrication, molding, and now contract manufacturing. SHL's advantage lies in our ability to minimize or eliminate the need for our partners to further outsource activities during development through to commercialization of a finished product," said SHL's Director of Business Development Taras Seniuch.

Visit SHL at Stand 307 to learn more about our products and services.


瑞健集團為領航全球先進藥物輸送系統產業的設計、研發、及製造龍頭。其事業據點涵蓋位於瑞士、瑞典、美國及台灣的現代化設計中心以及設立於亞洲的先進製造廠房。 瑞健主要客戶為世界知名藥廠以及生技公司,提供如自動化注射器,筆型注射器以及吸入器等高科技產品。瑞健持續投資於研發製造為開發新型高科技藥物輸送系統以符合市場趨勢,其中包括使用步驟簡化、注射器精密化、拋棄式/複用式多重選擇、劑量彈性化以及藥劑濃稠度之配合等。

瑞健目前全球已有超過 4,000 名員工,主要分為以下事業群:

SHL Medical 主要為製藥和生技企業設計、研發、及製造高科技藥物傳輸系統,也提供終端組裝、醫材標籤及包裝相關服務

SHL Healthcare 從事居家及醫院護理器材之研發製造

SHL Technologies 提供醫療科技及工業設備之 OEM 製造與相關服務